Clinical Trial

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased…

4 weeks ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July…

4 weeks ago

Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial

100% of patients enrolled achieved a partial response or betterMilder and less frequent drug-related adverse events were observed compared to…

4 weeks ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscapeDOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --…

4 weeks ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025Projected…

4 weeks ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue…

4 weeks ago

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of…

4 weeks ago

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

•  Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial•  DSMB Determination to Proceed with High Dose…

4 weeks ago

The Multiple Sclerosis Association of America (MSAA) Commemorates 15 Years of Highlighting Artists with MS

CHERRY HILL, N.J., June 20, 2024 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is proud to recognize 15…

4 weeks ago

“LaToya’s Story” Sheds Light on the Power of Personal Advocacy and the Importance of Health Equity, Wins Two Telly Awards

Mom bravely shares her story to raise awareness of breast cancer and clinical trial participation among Black women. NEW HAVEN,…

4 weeks ago